口服普萘洛尔治疗婴幼儿血管瘤临床应用新进展

New Progress in Clinical Application of Oral Propranolol in the Treatment of Infantile Hemangioma

婴幼儿血管瘤是最常见的儿童体表软组织良性肿瘤,发病率高、危害大,早期快速增生会造成严重的外观畸形及器官发育障碍。普萘洛尔已经成为治疗婴幼儿血管瘤的一线药物,但是在临床应用研究中诸多方面存在差异,甚至是争议。为了促进其合理应用及明确需要进一步研究方向,本文就普萘洛尔治疗婴幼儿血管瘤的治疗剂量、给药次数、药物的不良反应及影响血管瘤复发的因素等内容进行综述。

Infantile hemangioma is the most common benign tumor of soft tissue in children.It has a high incidence rate and great harm.Early rapid proliferation can cause serious appearance deformity and organ development disorders.Propranolol has become thefirst-line drug for the treatment of infantile hemangioma,but there are differences and even disputes in many aspects of clinical application researches.In order to promote its rational application and clarify the direction of further researches,the treatment dose,administration times,the adverse reactions of drugs and the factors of affecting the recurrence of hemangioma were reviewed.